ADVERSE EVENTS OF THE ARGUS II RETINAL PROSTHESIS: Incidence, Causes, and Best Practices for Managing and Preventing Conjunctival Erosion

Surgery and Intervention

Assessment of Postoperative Morphologic Retinal Changes by Optical Coherence Tomography in Recipients of an Electronic Retinal Prosthesis Implant

JAMA Ophthalmol.

Rizzo S, Cinelli L, Finocchio L, Tartaro R1, Santoro F, Gregori NZ

doi: 10.1001/jamaophthalmol.

Further Publications

Incidence of intraoperative and early postoperative adverse events in a large cohort of consecutive refractive lens exchange procedures

Am J Ophthalmol.

Schallhorn JM, Schallhorn SC, Teenan D, Hannan SJ, Pelouskova M, Venter JA

doi: 10.1016/j.ajo.2019.08.025.

Blindness and Vision ImpairmentMacular Diseases

Current Best Clinical Practices - Management of Neovascular AMD

Journal of VitreoRetinal Diseases

Brown D, Heier JS, Boyer DS, Freund KB, Kaiser P, Kim JE, Sarraf D

COMMENTED

Macular Diseases

Risk of Systemic Adverse Events Associated with Intravitreal Anti-VEGF Therapy for Diabetic Macular Edema in Routine Clinical Practice

Ophthalmology.

Maloney MH, Schilz SR, Herrin J, Sangaralingham LR, Shah ND, Barkmeier AJ

doi: 10.1016/

COMMENTED

Macular DiseasesRetinal Diseases

Risk of inflammation, retinal vasculitis and retinal occlusion-related events with brolucizumab: post-hoc review of HAWK and HARRIER

★ 2 Recommended by Dr habil. Gábor Márk Somfai, PhD, Faculty Member

Ophthalmology

Monés J, Srivastava SK, Jaffe GJ, Tadayoni R, Albini TA, Kaiser PK, Holz FG, Korobelnik JF, Kim IK, Pruente C, Murray TG, Heier JS

doi: 10.1016/j.ophtha.2020.11.011

Uveitis

Corticosteroid-Related Adverse Events Systematically Increase with Corticosteroid Dose in Noninfectious Intermediate, Posterior, or Panuveitis: Post Hoc Analyses from the VISUAL-1 and VISUAL-2 Trials

Ophthalmology.

Suhler EB, Thorne JE, Mittal M, Betts KA, Tari S, Camez A, Bao Y, Joshi A

doi: 10.1016/j.ophtha.2017.06.017.

COMMENTED

Retinal Diseases

PROPHYLACTIC LASER TREATMENT TO DECREASE THE INCIDENCE OF RETINAL DETACHMENT IN FELLOW EYES OF IDIOPATHIC GIANT RETINAL TEARS

Retina.

Verhoekx JSN, van Etten PG, Wubbels RJ, van Meurs JC, van Overdam KA

doi: 10.1097/IAE.

Glaucoma and Ocular PressureOcular OncologyRetinal Diseases

Mental stress as consequence and cause of vision loss: the dawn of psychosomatic ophthalmology for preventive and personalized medicine

EPMA Journal.

Sabel BA, Wang J, Cárdenas-Morales L, Faiq M, Heim C

doi: 10.1007/

Uveitis

Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial

Lancet.

Nguyen QD, Merrill PT, Jaffe GJ, Dick AD, Kurup SK, Sheppard J, Schlaen A, Pavesio C, Cimino L, Van Calster J, Camez AA, Kwatra NV, Song AP, Kron M, Tari S, Brézin AP

doi: 10.1016/

Related content

Assessment of Postoperative Morphologic Retinal Changes by Optical Coherence Tomography in Recipients of an Electronic Retinal Prosthesis Implant

Incidence of intraoperative and early postoperative adverse events in a large cohort of consecutive refractive lens exchange procedures

Current Best Clinical Practices - Management of Neovascular AMD

Risk of Systemic Adverse Events Associated with Intravitreal Anti-VEGF Therapy for Diabetic Macular Edema in Routine Clinical Practice

Risk of inflammation, retinal vasculitis and retinal occlusion-related events with brolucizumab: post-hoc review of HAWK and HARRIER

Corticosteroid-Related Adverse Events Systematically Increase with Corticosteroid Dose in Noninfectious Intermediate, Posterior, or Panuveitis: Post Hoc Analyses from the VISUAL-1 and VISUAL-2 Trials

PROPHYLACTIC LASER TREATMENT TO DECREASE THE INCIDENCE OF RETINAL DETACHMENT IN FELLOW EYES OF IDIOPATHIC GIANT RETINAL TEARS

Mental stress as consequence and cause of vision loss: the dawn of psychosomatic ophthalmology for preventive and personalized medicine

Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial